SBEM蛋白在乳腺癌微转移中作用的研究进展

Research Progress in Role of SBEM Protein in Micrometastasis of Breast Cancer

在发达国家,乳腺癌已成为第2位导致死亡的肿瘤性疾病。据统计,原位乳腺癌患者经手术切除癌肿后的5年生存率可达90%左右。然而,乳腺癌转移患者5年生存率不足25%,引起乳腺癌患者死亡的原因几乎均为远处播散和转移。肿瘤细胞转移的途径通常为血行转移、淋巴结转移和种植转移。早期发现肿瘤细胞微转移对乳腺癌的临床诊断、治疗、评估预后及降低患者病死率有重要意义。高灵敏性、特异性的肿瘤微转移标志物和适当的检测方法是早期诊断肿瘤微转移的关键。人乳腺上皮小黏蛋白广泛存在于乳腺和唾液腺中,已成为乳腺癌微转移方面研究的一个热点。

Breast cancer is the most common cancer among women and is the second leading cause of cancer death in women in developed countries. Latest statistics, the 5-year survival rate is approximately 90% for women after surgical resection of locally advanced breast cancer. However, if the cancer has metastasized, the average 5-year survival rate is less than 25%. Remote disperse and metastasis is the main cause of breast cancer-related death. The pathway of tumor cell metastasis are usually hematogenous metastasis,lymph node metastasis and implantation metastasis. The early detection of micrometastasis of tumor cells is important for clinical diagnosis, treatment, assessment of prognosis and reduction of the mortality. Using of high sensitivity and specificity tumor micrometastasis markers and a suitable detection method are the keys for early diagnosis of cancer micrometastasis. Small breast epithelial mucin（SBEM） protein ,which is highly expressed in normal breast and salivary glands,is used for the study of micrometastasis and has become a hot issue in the field.